AXT-1003

N/A

Report date: 2026/04/08 15:42:20
NME

Base Information

Drug NameAXT-1003
Drug Alias NameAXT-1003
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Renal Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAstoc Biomedical (Tianjin) Co LtdAxter Therapeutics Co LtdAxter Medical Technology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantLymphoma, Non-Hodgkin
Inactive IndicationsCarcinoma, Renal CellLymphoma, T-Cell, PeripheralNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A